ADDvise presents its forecast for the financial year 2015

ADDvise board of directors expects that the turnover for 2015 will be in the range of 160-170 MSEK, excluding acquisitions, with an EBITDA margin before any acquisition costs of at least 7 %.

The start of the first quarter 2015 has been strong in terms of new orders and the outlook for ADDvise markets looks favorable also for the rest of the year. This, in combination with the fact that efficiency improvements carried out during 2013 and 2014 are starting to show results, make the board of directors expect a turnover for 2015 in the range of 160-170 MSEK with an EBITDA margin before any acquisition costs of at least 7 %.

 

For further information, please contact:

Rikard Akhtarzand, CEO, +46 765-25 90 71

rikard.akhtarzand@addvisegroup.se

www.addvisegroup.com

 

About ADDvise Lab Solutions AB

ADDvise Lab Solutions AB (publ) is an expansive group which through its subsidiaries IM-Medico Svenska AB, KEBO Inredningar Sverige AB, ADDvise Tillquist AB, Sonesta Medical AB, Sonesta Medical Inc and Surgical Tables Inc. offers comprehensive solutions in the form of products and services to healthcare and research facilities. ADDvise Group's customers are located in both the private and public sectors. The Company's share is listed on First North Premier and Mangold Fondkommission AB, +46 8-503015 50, is the company's Certified Adviser and liquidity provider.

About Us

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. The Group has sales of about 250 MSEK. ADDvise shares are listed on Nasdaq First North Premier. Additional information is available at www.addvisegroup.com.